Chardan Capital

Analysts at Chardan Capital initiated coverage on Signal Genetics Inc (NASDAQ: SGNL) with a Buy rating. The target price for Signal Genetics is set to $2.50. Signal Genetics shares have dropped 80.76 percent over the past 52 weeks, while the S&P 500 index has surged 8.87 percent in the same...

Analysts at Chardan Capital initiated coverage on Lion Biotechnologies Inc (NASDAQ: LBIO) with a Buy rating. The target price for Lion Biotechnologies is set to $30. Lion Biotechnologies shares have gained 40.35 percent over the past 52 weeks, while the S&P 500 index has surged 12.25 percent in...

Analysts at Chardan Capital initiated coverage on UniQure NV (NASDAQ: QURE) with a Buy rating. The target price for UniQure is set to $40. UniQure shares have gained 139.73 percent over the past 52 weeks, while the S&P 500 index has surged 13.39 percent in the same period. UniQure shares rose 1...

OHR Pharmaceutical Inc (NASDAQ: OHRP) shares plunged Friday after its lead product for eye disease failed to meet the end-point of a mid-stage trial. The company changed hands recently at $2.86, down 67 percent. Chardan Capital's Gbola Amusa downgraded OHR to Neutral and cut his target by 60...

Analysts at Chardan Capital initiated coverage on Avalanche Biotechnologies, Inc. (NASDAQ: AAVL) with a Neutral rating. The target price for Avalanche Biotechnologies is set to $40. Avalanche Biotechnologies' shares rose 7.90% to close at $39.74 yesterday.

Analysts at Chardan Capital initiated coverage on Ophthotech Corporation (NASDAQ: OPHT) with a Buy rating. The target price for Ophthotech is set to $80. Ophthotech shares have gained 47.77% over the past 52 weeks, while the S&P 500 index has surged 14.85% in the same period. Ophthotech shares...